Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

Summary

A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.

Timeline

Start

2020-12-15

Primary completion

2021-12-31

Completion

2022-12-31

Drugs

Indications